Search Result

Results for "

murine xenograft models

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (7) Btk (2) c-Myc (1) Cannabinoid Receptor (1) Caspase (1) CD20 (1) CD3 (1) CDK (2) Constitutive Androstane Receptor (1) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (1) EGFR (2) Endogenous Metabolite (1) ERK (1) Ferroptosis (1) Glutathione Peroxidase (1) HDAC (1) Heme Oxygenase (HO) (1) Histone Methyltransferase (1) Interleukin Related (1) Keap1-Nrf2 (1) MEK (1) Mesothelin (1) Microtubule/Tubulin (3) mTOR (1) NF-κB (1) p38 MAPK (1) Phosphatase (1) PI3K (1) Pim (1) PROTACs (1) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (ROS) (2) STAT (1) Syk (1) Thymidylate Synthase (1) TNF Receptor (1) Toll-like Receptor (TLR) (4) Transmembrane Glycoprotein (1) WDR5 (1)
By Research Areas:	Cancer (23) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (1)

By Targets:

Akt (1)

Apoptosis (7)

Btk (2)

c-Myc (1)

Cannabinoid Receptor (1)

Caspase (1)

CD20 (1)

CD3 (1)

CDK (2)

Constitutive Androstane Receptor (1)

DNA/RNA Synthesis (1)

Drug-Linker Conjugates for ADC (1)

EGFR (2)

Endogenous Metabolite (1)

ERK (1)

Ferroptosis (1)

Glutathione Peroxidase (1)

HDAC (1)

Heme Oxygenase (HO) (1)

Histone Methyltransferase (1)

Interleukin Related (1)

Keap1-Nrf2 (1)

MEK (1)

Mesothelin (1)

Microtubule/Tubulin (3)

mTOR (1)

NF-κB (1)

p38 MAPK (1)

Phosphatase (1)

PI3K (1)

Pim (1)

PROTACs (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Reactive Oxygen Species (ROS) (2)

STAT (1)

Syk (1)

Thymidylate Synthase (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (4)

Transmembrane Glycoprotein (1)

WDR5 (1)

By Research Areas:

Cancer (23)

Inflammation/Immunology (3)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9964

Necitumumab 11F8; IMC-11F8; LY3012211	EGFR	Cancer
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .

HY-P991155

Ramantamig JNJ-79635322; JNJ-5322	CD3 TNF Receptor	Cancer
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .

HY-N2217

Rotundic acid	Akt mTOR p38 MAPK Apoptosis Phosphatase Interleukin Related NF-κB PI3K Keap1-Nrf2 Heme Oxygenase (HO) Toll-like Receptor (TLR) Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology Cancer
Rotundic acid is an orally effective triterpenoid with a K_d value of 51.3 µM for PTP1B. Rotundic acid downregulates the AKT/mTOR pro-survival pathway and modulates the MAPK pathway. Rotundic acid induces cell cycle S-phase arrest, DNA damage and apoptosis; it inhibits migration, invasion, angiogenesis and proliferation of cancer cells. Rotundic acid improves leptin sensitivity, regulates gut microbiota and reduces cellular senescence. Rotundic acid can be used in research related to hepatocellular carcinoma, obesity, aging, acute lung injury and type 2 diabetes .

HY-160142

UBX-382	PROTACs Btk Syk MEK ERK	Cancer
UBX-382 is an orally active BTK PROTAC degrader with a DC₅₀ of 4.56 nM. UBX-382 inhibits B-cell receptor signaling by targeting BTK. UBX-382 shows superior degradation activity for wild-type and mutant BTK proteins. UBX-382 inhibits tumor growth in murine xenograft models harboring wild-type or C481S mutant BTK-expressing TMD-8 cells. UBX-382 can be used for the study of B-cell-related blood cancers .

HY-12929

NSC756093 SU093	Pim Apoptosis	Cancer
NSC756093 (SU093) is a GBP1:PIM1 interaction inhibitor. NSC756093 binds to GBP1-PIM1 with a K_d of 38 nM. NSC756093 suppresses proliferation, reduces migration, induces G1 phase cell-cycle arrest, and increases apoptotic cell death in ovarian cancer cells. NSC756093 reduces cellular proteasomal activity, induces accumulation of ubiquitinated proteins, and restrains tumor progression and lung metastasis in murine ovarian cancer xenograft models. NSC756093 increases sensitivity of prostate cancer cells to Docetaxel (HY-B0011) and sensitizes GBP1-overexpressing ovarian cancer cells to Paclitaxel (HY-B0015). NSC756093 can be used for the research of prostate cancer and ovarian cancer .

HY-W654372

Tigloyl-L-carnitine chloride	Endogenous Metabolite	Cancer
Tigloyl-L-carnitine (chloride) is a short-chain acylacarnitine containing tiglic acid and L-carnitine. Tigloyl-L-carnitine (chloride) is increased in plasma in certain melanoma xenograft murine models. Tigloyl-L-carnitine (chloride) can be studied in research on melanoma .

HY-P991618

ST2485	Transmembrane Glycoprotein	Cancer
ST2485 is a monoclonal antitenascin antibody. ST2485 shows additivity in tenascin C binding in vitro as well as in a xenograft model. ST2485 binds human tenascin at an epitope partially shared with BC2. ST2485 cross-reacts with murine tenascin. ST2485 can be studied in antitumor research .

HY-P10793

Cyclic(YCDGFYACYMDV)	EGFR Apoptosis	Cancer
Cyclic(YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to HER2 on cancer cells. This transformation disrupts HER2 dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis). The inhibitory effects on HER2 positive breast cancer have been demonstrated to be effective in a murine xenograft model .

HY-161630

TLR8 agonist 8	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 8 (Compound II-72) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ of 0.25-1 μM. TLR8 agonist 8 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 8 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 89% .

HY-175041

GPX4-IN-18	Glutathione Peroxidase Reactive Oxygen Species (ROS) Cannabinoid Receptor Ferroptosis	Cancer
GPX4-IN-18 (Compound 17) is a ferrocene-containing inhibitor of glutathione peroxidase 4 (GPX4). GPX4-IN-18 is also an inducer of ferroptosis. GPX4-IN-18 can increase the production of ROS and malondialdehyde (MDA) levels in OS-RC-2 clear cell renal cell carcinoma cells. GPX4-IN-18 induces ferroptosis in HT-1080 cells with IC₅₀s of 0.007 μM (absence of ferrostatin-1) and 1.486 μM (presence of ferrostatin-1). GPX4-IN-18 reduces in vivo tumor volume and intratumoral GPX4 levels in OS-RC-2 xenograft murine model .

HY-16491

Tesetaxel DJ-927	Microtubule/Tubulin	Cancer
Tesetaxel (DJ-927) is an orally active and brain-penetrant taxane tubulin inhibitor. Tesetaxel inhibits tubulin depolymerization with an IC₅₀ of 0.44 μM. Tesetaxel inhibits cancer cells proliferation and shows potent antitumor activity against P-glycoprotein-positive cancer cells. Tesetaxel can be used for the research of cancer, such as solid tumors, liver metastasis, and advanced breast cancer .

HY-10823

OSI-7904L GW1843; 1843U89; OSI-7904	Thymidylate Synthase DNA/RNA Synthesis	Cancer
OSI-7904L (GW1843; 1843U89; OSI-7904) is a thymidylate synthase (TS) inhibitor with a K_i of 90 pM. OSI-7904L blocks de novo synthesis of thymidine nucleotides, DNA synthesis and induces cell death. OSI-7904L inhibits the growth of human cells, induces tumor regression, and achieves durable antitumor effects in mouse xenograft models. OSI-7904L can be used in research related to colon adenocarcinoma .

HY-151808

JS25	Btk	Neurological Disease Inflammation/Immunology Cancer
JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC₅₀ value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier .

HY-161629

TLR8 agonist 7	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 7 (Compound II-36) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ <250 nM. TLR8 agonist 7 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 7 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 98% .

HY-161631

TLR8 agonist 9	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 9 (Compound II-77) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ of 0.25-1 μM. TLR8 agonist 9 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 9 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 97% .

HY-172891

CDK9/HDAC1/HDAC3-IN-1	CDK HDAC Apoptosis	Cancer
CDK9/HDAC1/HDAC3-IN-1 is dual-functional inhibitor of CDK9 and HDAC. CDK9/HDAC1/HDAC3-IN-1 inhibits the protein activity of CDK9/HDAC/HDAC3 with IC₅₀s of 0.17  μM, 1.73  μM and 1.11 μM for CDK9, HDAC1, and HDAC3, respectively. CDK9/HDAC1/HDAC3-IN-1 inhibits cancer cells by inducing cell apoptosis and cell cycle arrest in the G2/M phase, as well as tumor growth in a murine TNBC MDA-MB-231 xenograft model. CDK9/HDAC1/HDAC3-IN-1 has a broad-spectrum anti-cancer activity, such as breast cancer, cervical cancer, and liver cancer .

HY-183354

HLC40	Histone Methyltransferase WDR5 Apoptosis Caspase	Cancer
HLC40 is a MLL1 histone methyltransferase inhibitor with an IC₅₀ of 0.82 μM by binding to WDR5. HLC40 inhibits proliferation of cancer cells, induces apoptosis and upregulates cleaved caspase-3 levels. HLC40 exhibits antitumor efficacy in a murine AML xenograft model .

HY-120120

DZ-2384	Microtubule/Tubulin	Cancer
DZ-2384 is a potent microtubule-targeting agent. DZ-2384 increases the rescue frequency and preserves the microtubule network in nonmitotic cells and primary neurons. DZ-2384 acts synergistically with anti-CTLA-4 immunotherapy in Taxane-sensitive and Taxane-resistant xenograft murine models of triple-negative breast cancer (TNBC). DZ-2384 exhibits potent antitumor activity in adult acute lymphocytic leukemia (ALL) models. DZ-2384 can be used for cancer research, such as TNBC and ALL ^[1][2].

HY-182387

NM404	Radionuclide-Drug Conjugates (RDCs)	Cancer
NM404 is a targeted radionuclide processing agent with slow clearance. Radioiodine-labeled NM404 is a small-molecule phospholipid ether analog that exhibits significant tumor uptake capacity and persistent tumor retention properties in more than 45 spontaneous and xenograft tumor models .

HY-181514

STAT3-IN-53	STAT CDK c-Myc Apoptosis	Cancer
STAT3-IN-53 (Compound L20) is a STAT3 inhibitor with a K_d value of 6.16 μM. STAT3-IN-53 binds directly to the SH2 domain of STAT3, inhibits phosphorylation at the Y705 site without affecting the total STAT3 protein level, and suppresses the IL-6/JAK/STAT3 pathway. STAT3-IN-53 downregulates the transcription and expression of cyclin-D1 and c-Myc. STAT3-IN-53 induces cell cycle arrest and promotes Apoptosis. STAT3-IN-53 exhibits anticancer activity against colorectal cancer .

HY-P992338

CT-1119	Mesothelin Constitutive Androstane Receptor	Inflammation/Immunology Cancer
CT-1119 is an autologous human anti-Mesothelin chimeric antigen receptor macrophage (CAR-M). CT-1119 mediates CAR-dependent, antigen-dependent functional activities. CT-1119 acts as a phagocytosis inducer, tumor cell killer, pro-inflammatory cytokine inducer, and M1 macrophage polarizer. CT-1119 exhibits stronger resistance to M2 repolarization and reduces tumor burden in a mouse lung cancer xenograft model. CT-1119 can be used for the research of mesothelin-expressing solid tumors .

HY-P11779

Ac-RKAA-PABC-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
Ac-RKAA-PABC-MMAE is a Drug-Linker Conjugates for ADC. Ac-RKAA-PABC-MMAE consists of the ADC Cytotoxin MMAE (HY-15162) and a linker. Ac-RKAA-PABC-MMAE can be used for synthesis of ADCs .

HY-P992417

MT-3724	CD20 Apoptosis	Cancer
MT-3724 is a CD20-targeted endotoxin B. MT-3724 binds to CD20, triggers receptor internalization, traffics to the endoplasmic reticulum, and induces permanent ribosomal inactivation to mediate cell killing. MT-3724 can inhibit protein synthesis and promote tumor cell apoptosis. MT-3724 can be used for the research of relapsed or refractory B-cell non-Hodgkin’s lymphomas and diffuse large B-cell lymphoma .

Cat. No.	Product Name	Target	Research Area